Romm Preston S 4

4 · Obagi Medical Products, Inc. · Filed Apr 29, 2013

Form 4

Period: 2013-04-25

CFO

Transactions

Disposition to Issuer
Stock option (right to buy)
2013-04-25$14.00/sh−71,195$996,730→ 0 total
Exercise: $10.00Exp: 2018-07-01→ Common stock (71,195 underlying)
Disposition to Issuer
Stock option (right to buy)
2013-04-25$12.51/sh−50,000$625,500→ 0 total
Exercise: $11.49Exp: 2020-03-08→ Common Stock (50,000 underlying)
Disposition to Issuer
Stock option (right to buy)
2013-04-25$14.29/sh−50,000$714,500→ 0 total
Exercise: $9.71Exp: 2021-11-29→ Common Stock (50,000 underlying)
Disposition to Issuer
Stock option (right to buy)
2013-04-25$11.30/sh−50,000$565,000→ 0 total
Exercise: $12.70Exp: 2022-05-01→ Common Stock (50,000 underlying)

Footnotes (1)

[F1]This stock option immediately vested in full and was converted into the right to receive cash in an amount equal to the product of (A) the total number of shares subject to the option, and (B) the difference between $24.00 minus the exercise price per share of the option, pursuant to the terms of the Agreement and Plan of Merger, dated as of March 19, 2013, among the issuer, Odysseus Acquisition Corp., Valeant Pharmaceuticals International and Valeant Pharmaceuticals International, Inc., as amended, and the issuer's 2005 Stock Incentive Plan, as amended, and as approved by the issuer's Compensation Committee.

Documents

1 file